| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | ideZ |
| Uniprot No | Q0PIW1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-349aa |
| 氨基酸序列 | DDYQRNAAEVYAKEVPHQITSVWTKGVTPLTPEQFRYNNEDVIHAPYLAHQGWYDITKVFDGKDNLLCGAATAGNMLHWWFDQNKTEIEAYLSKHPEKQKIIFNNQELFDLKAAIDTKDSQTNSQLFNYFRDKAFPNLSARQLGVMPDLVLDMFINGYYLNVFKTQSTDVNRPYQDKDKRGGIFDAVFTRGDQTTLLTARHDLKNKGLNDISTIIKQELTEGRALALSHTYANVSISHVINLWGADFNAEGNLEAIYVTDSDANASIGMKKYFVGINAHGHVAISAKKIEGENIGAQVLGLFTLSSGKDIWQKLS |
| 预测分子量 | 37.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IdeZ重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: *IdeZ: A novel IgG-binding protein from Streptococcus equi subsp. zooepidemicus*
**作者**: Halling, C., et al. (2008)
**摘要**: 该研究首次报道了马链球菌亚种中IdeZ蛋白的IgG结合特性，阐明了其在免疫逃逸中的作用，并成功通过重组表达验证了其功能。
2. **文献名称**: *Structural characterization of recombinant IdeZ protease and its substrate specificity*
**作者**: Smith, R.J., et al. (2015)
**摘要**: 通过X射线晶体学解析了重组IdeZ的三维结构，揭示了其底物结合位点的关键氨基酸残基，并证明其特异性切割IgG的铰链区。
3. **文献名称**: *Application of recombinant IdeZ for antibody fragmentation in therapeutic development*
**作者**: Lee, M., et al. (2020)
**摘要**: 研究利用大肠杆菌表达的重组IdeZ高效制备抗体Fab片段，展示了其在生物制药领域简化抗体工程流程的潜力。
---
**备注**：
1. 上述文献为示例，实际研究中建议通过PubMed或Google Scholar以关键词“IdeZ recombinant protein”或“Streptococcus IdeZ”检索最新论文。
2. IdeZ常与链球菌属(如马链球菌)的免疫逃逸机制相关，研究多聚焦于其蛋白酶活性、结构及应用开发。
**Background of IdeZ Recombinant Protein**
IdeZ, an immunoglobulin G (IgG)-degrading enzyme, is a bacterial protease originally identified in *Streptococcus zooepidemicus*, a pathogen affecting animals and occasionally humans. This enzyme specifically cleaves IgG antibodies at the hinge region, disrupting their effector functions—a strategy employed by the bacterium to evade host immune defenses. Such proteolytic activity positions IdeZ as a critical virulence factor in host-pathogen interactions, enabling bacterial survival within infected hosts.
The recombinant version of IdeZ is produced via genetic engineering, typically using heterologous expression systems like *Escherichia coli*. Cloning the *ideZ* gene into expression vectors allows large-scale production and purification of the protein, ensuring consistency and scalability for research or industrial applications. Recombinant IdeZ retains the enzymatic specificity of its native counterpart, making it a valuable tool for studying antibody structure-function relationships, immune evasion mechanisms, and bacterial pathogenesis.
In biotechnology, IdeZ is utilized to generate antigen-binding fragments (Fabs) from full-length IgG antibodies. This application is particularly useful in therapeutic development, diagnostics, and structural biology, as Fabs offer advantages in tissue penetration and reduced immunogenicity compared to intact antibodies. Additionally, IdeZ’s ability to cleave IgG under mild conditions preserves antigen-binding activity, unlike chemical fragmentation methods.
Research on IdeZ also contributes to antimicrobial strategies, such as designing inhibitors to block its activity, potentially mitigating bacterial infections. Furthermore, its role in dissecting IgG-mediated immune responses has implications for developing antibody-based therapies and understanding autoimmune diseases. Overall, recombinant IdeZ bridges microbiological research and biotechnological innovation, offering both mechanistic insights and practical applications.
×
